[go: up one dir, main page]

CO2019009060A2 - Moduladores del canal de potasio - Google Patents

Moduladores del canal de potasio

Info

Publication number
CO2019009060A2
CO2019009060A2 CONC2019/0009060A CO2019009060A CO2019009060A2 CO 2019009060 A2 CO2019009060 A2 CO 2019009060A2 CO 2019009060 A CO2019009060 A CO 2019009060A CO 2019009060 A2 CO2019009060 A2 CO 2019009060A2
Authority
CO
Colombia
Prior art keywords
potassium channel
channel modulators
disorders
diseases
treating
Prior art date
Application number
CONC2019/0009060A
Other languages
English (en)
Inventor
Dipak Vasantrao Amrutkar
Kelly Foster
Thomas Amos Jacobsen
Martin R Jefson
Gregg F Keaney
Janus Schreiber Larsen
Karin Sandager Nielsen
Original Assignee
Cadent Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadent Therapeutics Inc filed Critical Cadent Therapeutics Inc
Publication of CO2019009060A2 publication Critical patent/CO2019009060A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)

Abstract

Se proporcionan compuestos y sales farmacéuticamente aceptables de los mismos, que son útiles para tratar una variedad de enfermedades, trastornos o condiciones, asociados con canales de potasio.
CONC2019/0009060A 2017-01-23 2019-08-22 Moduladores del canal de potasio CO2019009060A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762449270P 2017-01-23 2017-01-23
PCT/US2018/014792 WO2018136917A1 (en) 2017-01-23 2018-01-23 Potassium channel modulators

Publications (1)

Publication Number Publication Date
CO2019009060A2 true CO2019009060A2 (es) 2019-08-30

Family

ID=61188924

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0009060A CO2019009060A2 (es) 2017-01-23 2019-08-22 Moduladores del canal de potasio

Country Status (30)

Country Link
US (4) US9975886B1 (es)
EP (1) EP3571193B1 (es)
JP (1) JP6997197B2 (es)
KR (1) KR102664772B1 (es)
CN (1) CN110198935B (es)
AR (1) AR110770A1 (es)
BR (1) BR112019014814B1 (es)
CL (1) CL2019002031A1 (es)
CO (1) CO2019009060A2 (es)
CU (1) CU24560B1 (es)
CY (1) CY1125463T1 (es)
DK (1) DK3571193T3 (es)
EA (1) EA036668B1 (es)
ES (1) ES2906078T3 (es)
HR (1) HRP20220079T1 (es)
HU (1) HUE057710T2 (es)
IL (1) IL267954B (es)
LT (1) LT3571193T (es)
MX (1) MX376080B (es)
MY (1) MY195123A (es)
PH (1) PH12019501678A1 (es)
PL (1) PL3571193T3 (es)
PT (1) PT3571193T (es)
RS (1) RS62899B1 (es)
SG (1) SG11201905893WA (es)
SI (1) SI3571193T1 (es)
TW (1) TWI751271B (es)
UA (1) UA123810C2 (es)
WO (1) WO2018136917A1 (es)
ZA (1) ZA201904458B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210545A1 (en) * 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
PT3571193T (pt) 2017-01-23 2022-03-25 Cadent Therapeutics Inc Moduladores dos canais de potássio
US11993586B2 (en) * 2018-10-22 2024-05-28 Novartis Ag Crystalline forms of potassium channel modulators
CN118985622B (zh) * 2024-07-05 2025-12-02 云南大学 一种吡唑类化合物在防治植物根结线虫中的应用

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6059883B2 (ja) 1978-05-08 1985-12-27 北興化学工業株式会社 農園芸用殺菌剤
GB2183243B (en) 1985-10-09 1990-01-24 Nippon Oil Co Ltd Process for preparing oil-soluble nitrogen-containing compounds
AU3752589A (en) 1988-05-16 1989-12-12 Georgia State University Research Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
LU87304A1 (fr) 1988-07-29 1990-02-07 Oreal Nouveaux derives d'ureylene triamino-2,4,6 pyrimidine oxyde-3,leur preparation et leur utilisation en cosmetique et dermopharmacie
JPH02282251A (ja) 1989-04-24 1990-11-19 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
DE3922735A1 (de) 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
DE4034762A1 (de) 1990-11-02 1992-05-07 Hoechst Ag Pyridylpyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
HU209678B (en) 1992-06-09 1994-10-28 Richter Gedeon Vegyeszet Process for producing biologically active eburnamenin-14-carbonyl-amino derivatives and pharmaceutical compositions containing them
DK72693D0 (da) 1993-06-18 1993-06-18 Lundbeck & Co As H Compounds
CA2133355A1 (en) 1993-10-04 1995-04-05 Itaru Nitta Method for producing polypeptide
WO1998006709A1 (en) 1996-08-14 1998-02-19 Takeda Chemical Industries, Ltd. Cyclic urea compounds, their production and use as herbicides
DE19642863A1 (de) 1996-10-17 1998-04-23 Bayer Ag Amide
US6117973A (en) 1997-02-24 2000-09-12 Georgia Tech Research Corp. PNA monomers with electron donor or acceptor
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
JPH11282132A (ja) 1998-03-27 1999-10-15 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の処理方法
JP2000072695A (ja) 1998-08-24 2000-03-07 Sumitomo Pharmaceut Co Ltd 環状化合物
JP2000075449A (ja) 1998-08-31 2000-03-14 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料の現像方法
ES2307528T3 (es) 1999-09-04 2008-12-01 Astrazeneca Ab Amidas como inhibidores para la piruvato deshidrogenasa.
WO2001032170A1 (en) 1999-09-13 2001-05-10 Swope David M Composition and method for decreasing neurologic symptomatology
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
CA2412208C (en) 2000-06-29 2009-08-18 Neurosearch A/S Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
AU2002213467A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
CN1486302A (zh) 2000-12-07 2004-03-31 CV���ƹ�˾ 作为抗冠状动脉疾病或动脉硬化的abca-1加强化合物的取代1,3,5-三嗪和嘧啶
NZ535574A (en) 2001-01-16 2006-07-28 Astrazeneca Ab Therapeutic heterocyclic compounds
CA2433950A1 (en) 2001-01-16 2002-07-18 Timothy Davenport Therapeutic chromone compounds
BR0206514A (pt) 2001-01-16 2004-01-06 Astrazeneca Ab Composto, método de tratamento de um ser humano ou animal que sofre de enxaqueca, uso do composto, composição farmacêutica, e, processo para preparar um composto
AU2002258400A1 (en) 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
BR0208956A (pt) * 2001-04-16 2004-07-13 Tanabe Seiyaku Co Abridor de canais de k ativados por cálcio de grande condutância
EP1270551A1 (en) 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Urea derivatives with antiproteolytic activity
US7378432B2 (en) 2001-09-14 2008-05-27 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
US7012077B2 (en) 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
AU2003212634A1 (en) 2002-03-11 2003-09-22 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
US20040082627A1 (en) 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
DE60305053T2 (de) 2002-08-19 2006-08-31 Glaxo Group Ltd., Greenford Pyrimidinderivate als selektive cox-2-inhibitoren
JP2005536554A (ja) 2002-08-23 2005-12-02 ユニバーシティ オブ コネチカット 新規なビフェニル及びビフェニル様カンナビノイド
GB0311201D0 (en) 2003-05-15 2003-06-18 Merck Sharp & Dohme Therapeutic agents
US7589092B2 (en) 2003-06-20 2009-09-15 Koronis Pharmaceuticals, Incorporated Prodrugs of heteroaryl compounds
US20050070531A1 (en) 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2005035507A2 (en) 2003-10-10 2005-04-21 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
CA2541509C (en) 2003-10-17 2014-06-10 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
MXPA06005735A (es) 2003-11-24 2006-08-17 Hoffmann La Roche Pirazolil e imidazolil pirimidinas.
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
WO2005095357A2 (en) 2004-03-30 2005-10-13 Taisho Pharmaceutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
JP4926943B2 (ja) 2004-04-13 2012-05-09 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２産生を阻害する二塩
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
RU2007110731A (ru) 2004-09-23 2008-10-27 Редди Юс Терапевтикс Новые соединения пиримидина, способ их получения и содержащие их композиции
GB0422556D0 (en) 2004-10-11 2004-11-10 Syngenta Participations Ag Novel insecticides
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
WO2006065590A2 (en) 2004-12-16 2006-06-22 Xtl Biopharmaceuticals Inc. Pyridine and pyrimidine antiviral compositions
WO2006074057A2 (en) 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US20090069384A1 (en) 2005-01-19 2009-03-12 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
EP1844013A1 (en) 2005-01-19 2007-10-17 Biolipox AB Indoles useful in the treatment of inflammation
EP1841735B1 (en) 2005-01-19 2011-03-09 Biolipox AB Indoles useful in the treatment of inflammation
EP1838669A1 (en) 2005-01-19 2007-10-03 Biolipox AB Indoles useful in the treatment of inflammation
JP2008527030A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
CN101115736A (zh) * 2005-03-14 2008-01-30 神经研究公司 钾通道调节剂和它们的医药用途
JP4966958B2 (ja) 2005-03-14 2012-07-04 ノイロサーチ アクティーゼルスカブ カリウムチャネル調節剤及び医療における使用
WO2006100212A1 (en) * 2005-03-22 2006-09-28 Neurosearch A/S Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use
US20090036475A1 (en) 2005-03-22 2009-02-05 Neurosearch A/S Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use
US20060156481A1 (en) 2005-03-22 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
DE102005025315A1 (de) 2005-06-02 2006-12-14 Merck Patent Gmbh Ionische Flüssigkeiten mit niedriger Viskosität
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
KR101354114B1 (ko) 2005-06-14 2014-01-24 타이젠 바이오테크놀러지 컴퍼니 리미티드 피리미딘 화합물
AR054510A1 (es) 2005-06-14 2007-06-27 Schering Corp Compuestos heterociclicos como inhibidores de aspartil proteasas y composiciones farmaceuticas que los comprenden.
CA2617170A1 (en) 2005-07-30 2007-02-08 Astrazeneca Ab Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
DE102005043165A1 (de) 2005-09-12 2007-03-22 Merck Patent Gmbh Metallkomplexe
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
FR2892859B1 (fr) 2005-10-27 2008-06-06 Commissariat Energie Atomique Procede de greffage de molecules d'interet sur des surfaces inorganiques, surfaces obtenues et applications
EP1962892A4 (en) 2005-11-22 2011-10-12 Univ South Florida INHIBITION OF CELL PROLIFERATION
CA2633541A1 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
TW200730476A (en) 2005-12-12 2007-08-16 Genelabs Tech Inc N-(5-membered aromatic ring)-amido anti-viral compounds
JP2009519995A (ja) 2005-12-20 2009-05-21 ノイロサーチ アクティーゼルスカブ 呼吸器疾患の治療のためのカリウムチャンネル調節剤としての２−ピリジン−２−イル−キナゾリン誘導体
AU2007226582B2 (en) 2006-03-13 2012-07-05 Revvity Health Sciences, Inc. Substrates and internal standards for mass spectroscopy detection
US20090318507A2 (en) 2006-05-02 2009-12-24 Chris Rundfeldt Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia Like Symptoms
WO2008005538A2 (en) 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
AU2007279442A1 (en) 2006-08-03 2008-02-07 Prosensa Technologies B.V. Antibiotic composition
US20110144140A1 (en) 2006-09-07 2011-06-16 Eriksen Birgitte L Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
WO2008040753A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
WO2008052861A2 (de) 2006-10-10 2008-05-08 Proionic Production Of Ionic Substances Gmbh & Co Keg Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten
TW200827368A (en) 2006-11-21 2008-07-01 Genelabs Tech Inc Amido anti-viral compounds
CN101679371A (zh) 2006-12-04 2010-03-24 艾美罗股份公司 作为腺苷受体拮抗剂的取代的嘧啶
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
CA2675558A1 (en) 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
US8940900B2 (en) 2007-02-28 2015-01-27 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
WO2008110891A2 (en) 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
WO2008116911A1 (en) 2007-03-28 2008-10-02 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
JP2010522720A (ja) 2007-03-28 2010-07-08 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
WO2008125811A1 (en) 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
JP5111039B2 (ja) 2007-09-27 2012-12-26 富士フイルム株式会社 重合性化合物、重合開始剤、および染料を含有する光硬化性組成物
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
RU2434634C1 (ru) 2008-02-08 2011-11-27 Шисейдо Компани Лтд. Отбеливающий агент и композиция для кожи для наружного применения
AU2009219070A1 (en) 2008-02-28 2009-09-03 Saint Mary's University Ionic liquids comprising ligands containing positively charged heterocyclic ring useful as catalyst and for metal extractions
JP2011515462A (ja) 2008-03-27 2011-05-19 アウククランド ウニセルビセス リミテッド 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用
EP2280948A1 (en) 2008-04-09 2011-02-09 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
US8642778B2 (en) 2008-05-28 2014-02-04 Merck Patent Gmbh Ionic liquids
TW201006830A (en) 2008-06-11 2010-02-16 Astrazeneca Ab Chemical compounds
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
DE102008031480A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Salze enthaltend ein Pyrimidincarbonsäure-Derivat
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
EP2331527A1 (en) 2008-09-02 2011-06-15 NeuroSearch A/S Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
CN101684098A (zh) 2008-09-24 2010-03-31 中国科学院上海药物研究所 一类5-脂氧酶抑制剂及其制备方法、药物组合物和应用
US8268838B2 (en) 2008-09-26 2012-09-18 Neurosearch A/S Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
AR074870A1 (es) 2008-12-24 2011-02-16 Palau Pharma Sa Derivados de pirazolo (1,5-a ) piridina
WO2010120994A2 (en) 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
EP2440559B1 (en) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
EP2445343B1 (en) 2009-06-25 2021-08-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
WO2010151797A2 (en) 2009-06-26 2010-12-29 University Of Massachusetts Compounds for modulating rna binding proteins and uses therefor
PL2451794T3 (pl) 2009-07-08 2016-07-29 Baltic Bio Ab Pochodne 1,2,4-tiazolidyn-3-onu i ich zastosowanie do leczenia nowotworu
WO2011008931A2 (en) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
CN102596932A (zh) 2009-09-04 2012-07-18 拜耳医药股份有限公司 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
AR078278A1 (es) 2009-09-09 2011-10-26 Vifor Int Ag Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
US9181414B2 (en) 2009-11-13 2015-11-10 Plastipak Packaging, Inc. Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions
FR2954317B1 (fr) 2009-12-23 2012-01-27 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
AT509266B1 (de) 2009-12-28 2014-07-15 Univ Wien Tech Substituierte pyridine und pyrimidine
AU2010347233B2 (en) 2010-03-01 2015-06-18 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
MX2012013130A (es) 2010-05-13 2013-04-11 Amgen Inc Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10.
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
KR20120018236A (ko) 2010-07-23 2012-03-02 현대약품 주식회사 치환된 피리미디닐 유도체 및 이의 제조방법
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
AR082498A1 (es) 2010-08-20 2012-12-12 Gruenenthal Gmbh Derivados ciclicos de carboxamida y urea sustituidos como ligandos del receptor de vainiloide
KR101983979B1 (ko) * 2010-08-27 2019-05-30 그뤼넨탈 게엠베하 Ｋｃｎｑ２／３ 조절제로서의 치환된 ２-옥소- 및 ２-티옥소-디하이드로퀴놀린-３-카복스아미드
US20120082872A1 (en) 2010-09-30 2012-04-05 Basf Se Additive for electrolytes
WO2012052540A1 (en) 2010-10-21 2012-04-26 Universitaet Des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
DK2835131T3 (en) 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
WO2012109343A2 (en) 2011-02-08 2012-08-16 President And Fellows Of Harvard College Iron complexes and methods for polymerization
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102731492B (zh) 2011-03-30 2016-06-29 江苏恒瑞医药股份有限公司 环己烷类衍生物、其制备方法及其在医药上的应用
WO2012154880A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
US9556166B2 (en) 2011-05-12 2017-01-31 Proteostasis Therapeutics, Inc. Proteostasis regulators
US9518068B2 (en) 2011-05-31 2016-12-13 Merck Patent Gmbh Compounds containing hydrido-tricyano-borate anions
JP6266509B2 (ja) 2011-06-03 2018-01-24 マサチューセッツ インスティテュート オブ テクノロジー Ｚ選択的閉環メタセシス反応
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
JP2013020223A (ja) 2011-06-17 2013-01-31 Fujifilm Corp 高分子フィルム、セルロースエステルフィルム、偏光板、及び液晶表示装置
CA2846659A1 (en) 2011-08-29 2013-03-07 Ptc Therapeutics, Inc. Antibacterial compounds and methods for use
JP5741850B2 (ja) 2011-09-13 2015-07-01 コニカミノルタ株式会社 光学フィルム、それを含む偏光板および液晶表示装置
JP5857713B2 (ja) 2011-12-15 2016-02-10 コニカミノルタ株式会社 光学フィルム、偏光板、及び液晶表示装置
WO2013120040A1 (en) 2012-02-10 2013-08-15 Children's Medical Center Corporation Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy
DE102012006896A1 (de) 2012-04-05 2013-10-10 Merck Patent Gmbh Silikate mit organischen Kationen
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
FR2992317B1 (fr) 2012-06-22 2016-05-13 Diverchim Procede de preparation de peptides chiraux
US20150197503A1 (en) 2012-07-27 2015-07-16 Bial-Portela & Cª, S.A. Process for the synthesis of substituted urea compounds
WO2014031681A1 (en) 2012-08-20 2014-02-27 The University Of Chicago Inhibiting gram positive bacteria
WO2014031872A2 (en) 2012-08-23 2014-02-27 The Broad Institute, Inc. Small molecule inhibitors for treating parasitic infections
CN107098899B (zh) 2012-09-18 2019-09-06 赫普泰雅治疗有限公司 作为毒蕈碱的m1受体激动剂的二环氮杂化合物
DE102012021452A1 (de) 2012-10-31 2014-04-30 Merck Patent Gmbh Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion
EP2920148B1 (en) 2012-11-16 2019-06-12 The Regents of the University of California Pictet-spengler ligation for protein chemical modification
ES2469290B2 (es) 2012-12-17 2015-01-26 Ocupharm Diagnostics S.L. Mejora en la aplicación tópica de fármacos oculares mediante la administración de nucleótidos
US9279094B2 (en) 2012-12-21 2016-03-08 Afton Chemical Corporation Friction modifiers for use in lubricating oil compositions
US9499762B2 (en) 2012-12-21 2016-11-22 Afton Chemical Corporation Additive compositions with a friction modifier and a detergent
JP6450323B2 (ja) 2013-01-07 2019-01-09 ユニバーシティ オブ サザン カリフォルニア デオキシウリジントリホスファターゼ阻害剤
WO2014108487A1 (en) 2013-01-10 2014-07-17 Universite D'aix-Marseille P-stereogenic chiral precursor of chiral ligands and use thereof
WO2014134141A1 (en) 2013-02-26 2014-09-04 President And Fellows Of Harvard College Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer
HUE057527T2 (hu) 2013-03-12 2022-05-28 Vertex Pharma DNS-PK inhibitorok
CA2908695A1 (en) 2013-04-05 2014-10-09 Salk Institute For Biological Studies Ppar agonists
WO2015000548A1 (de) 2013-07-02 2015-01-08 Merck Patent Gmbh Organische elektrolumineszenzvorrichtung
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
AU2014295000A1 (en) 2013-07-25 2016-02-18 Fondazione Telethon Inhibitors of FAPP2 and uses thereof
US9701635B2 (en) 2013-07-26 2017-07-11 The Regents Of The University Of California C-H fluorination of heterocycles with silver (II) fluoride
WO2015031725A1 (en) 2013-08-30 2015-03-05 President And Fellows Of Harvard College Transition metal-catalyzed imidation of arenes
DE102013016324A1 (de) 2013-10-04 2015-04-09 Merck Patent Gmbh Perfluoralkylfluor- oder Perfluoralkylchlorgermanate
KR20160063366A (ko) 2013-10-21 2016-06-03 메르크 파텐트 게엠베하 Btk 저해제로서 헤테로아릴 화합물 및 이들의 용도
WO2015069752A1 (en) 2013-11-05 2015-05-14 The Regents Of The University Of California Acetylcholine binding protein ligands, cooperative nachr modulators and methods for making and using
CN103626741A (zh) 2013-11-26 2014-03-12 苏州大学 具有腺苷受体拮抗剂活性的杂环氨基嘧啶化合物
CN106029804B (zh) 2013-11-29 2019-09-24 普罗奥尼克股份有限公司 使用微波辐射使粘合剂固化的方法
WO2015084936A1 (en) 2013-12-04 2015-06-11 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
ES2702951T3 (es) 2014-04-04 2019-03-06 Syros Pharmaceuticals Inc Inhibidores de quinasas dependientes de ciclina 7 (cdk7)
US10308648B2 (en) 2014-10-16 2019-06-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
GB201502412D0 (en) 2015-02-13 2015-04-01 Canbex Therapeutics Ltd Therapeutic use
WO2017044889A1 (en) 2015-09-10 2017-03-16 The Regents Of The University Of California Lrh-1 modulators
US20170299609A1 (en) 2016-04-18 2017-10-19 Wright State University Treatment of amyotrophic lateral sclerosis with sk channel activators
WO2017210545A1 (en) * 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
US20170355708A1 (en) 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
WO2018136918A1 (en) 2017-01-23 2018-07-26 Cadent Therapeutics, Inc. Methods for the treatment of tremors by positive modulation of sk channels
PT3571193T (pt) 2017-01-23 2022-03-25 Cadent Therapeutics Inc Moduladores dos canais de potássio

Also Published As

Publication number Publication date
JP2020504165A (ja) 2020-02-06
HUE057710T2 (hu) 2022-05-28
US20210380571A1 (en) 2021-12-09
CL2019002031A1 (es) 2019-10-04
CN110198935B (zh) 2022-05-31
IL267954A (en) 2019-09-26
EP3571193A1 (en) 2019-11-27
KR102664772B1 (ko) 2024-05-10
HRP20220079T1 (hr) 2022-04-15
BR112019014814A2 (pt) 2020-02-27
DK3571193T3 (da) 2022-01-17
MX2019008682A (es) 2019-09-18
ES2906078T3 (es) 2022-04-13
US20190352293A1 (en) 2019-11-21
TWI751271B (zh) 2022-01-01
US9975886B1 (en) 2018-05-22
PH12019501678A1 (en) 2020-06-01
SI3571193T1 (sl) 2022-04-29
CY1125463T1 (el) 2024-02-16
EA201991488A1 (ru) 2019-12-30
CU20190066A7 (es) 2020-03-04
CU24560B1 (es) 2021-12-08
WO2018136917A1 (en) 2018-07-26
RS62899B1 (sr) 2022-03-31
TW201838985A (zh) 2018-11-01
UA123810C2 (uk) 2021-06-02
PL3571193T3 (pl) 2022-04-25
BR112019014814B1 (pt) 2024-03-12
CN110198935A (zh) 2019-09-03
LT3571193T (lt) 2022-02-10
MY195123A (en) 2023-01-11
SG11201905893WA (en) 2019-08-27
US10717728B2 (en) 2020-07-21
EA036668B1 (ru) 2020-12-07
EP3571193B1 (en) 2021-12-01
JP6997197B2 (ja) 2022-01-17
ZA201904458B (en) 2023-04-26
MX376080B (es) 2025-03-07
KR20190110572A (ko) 2019-09-30
US10351553B2 (en) 2019-07-16
AR110770A1 (es) 2019-05-02
PT3571193T (pt) 2022-03-25
IL267954B (en) 2022-02-01
US20180215746A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
UY37554A (es) (aza)indol- y benzofuran-3-sulfonamidas
CO2020000527A2 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp
CR20210592A (es) Moduladores de la vía integrada del estrés
CR20170392A (es) Compuestos bicíclicos de sulfonamida cetona
ECSP19075354A (es) Moduladores de k-ras
MX2020011745A (es) Terapias genicas para los trastornos lisosomales.
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
CL2020003174S1 (es) Dispositivo para administración de dosis.
ECSP17073743A (es) Moduladores de k-ras
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
CO2018012946A2 (es) Moduladores de la vía de estrés integrada
CO2019009060A2 (es) Moduladores del canal de potasio
CO2021009009A2 (es) Moduladores de la expresión de hsd17b13
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
CO2018000224A2 (es) Compuestos inhibidores de la señalización de la vía de notch
CR20220187A (es) Formas cristalinas de estado sólido de un modulador selectivo de canales de potasio
MX2017005715A (es) Potentes moduladores de gamma-secretasa.
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
JOP20210210A1 (ar) منتج للعناية بالفم
MX2021004647A (es) Formas cristalinas de moduladores de los canales de potasio.
CO2021013311A2 (es) Inhibidores del canal de potasio novedosos
CL2022001417A1 (es) Proceso para los productos de sintegas.
CL2019001121S1 (es) Cepillo de dientes.
TH1901004464A (th) มอดูเลเตอร์ของช่องโพแทสเซียม